AstraZeneca on Wednesday said its Imfinzi drug combined with chemotherapy reduced the risk of death by 20% in people with advanced biliary tract cancer (BTC) after results from a phase III clinical trial.
Worldwide, 210,000 people are diagnosed with BTC each year with between 5%-15% surviving more than five years.
In a separate statement, the company said a combination of Imfinzi with tremelimumab antibodies showed an unprecedented survival rate in liver-cancer patients.
Results from its Himalaya Phase III trial showed a single dose of tremelimumab added to Imfinzi showed unprecedented survival in first-line unresectable liver cancer. It said that 31% of patients were alive after three years.
